The TORCH trial.
作者： Louise Rosalyn Carter , Raffaele Califano
DOI: 10.3978/J.ISSN.2218-6751.2012.10.04
关键词:
摘要: Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related death worldwide (1). Unfortunately the majority patients are diagnosed with advanced disease where treatment intent is palliative. The mainstay treatment, until recently, has been platinum based doublet chemotherapy which improves symptoms and prolongs survival compared to best supportive care (2). Increased interest in molecular pathways drive growth led development targeted agents such as epidermal factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib gefitinib both approved for use first-line NSCLC harbouring an EGFR activating mutation secondor third-line (erlotinib) NSCLC, independently mutational status.
amegroups.com参考文章(18)
Tony Mok, Yi Long Wu, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Elena Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Kate Jin, Matt Truman, Jin Soo Lee, A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. Journal of Clinical Oncology. ,vol. 30, pp. 7519- 7519 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.7519
Giuseppe Giaccone, Marielle Gallegos Ruiz, Thierry Le Chevalier, Nick Thatcher, Egbert Smit, Jose Antonio Rodriguez, Pasi Janne, Dalila Oulid-Aissa, Jean-Charles Soria, Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study Clinical Cancer Research. ,vol. 12, pp. 6049- 6055 ,(2006) , 10.1158/1078-0432.CCR-06-0260
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massuti, Jose Luis Gonzalez-Larriba, Luis Paz-Ares, Isabel Bover, Rosario Garcia-Campelo, Miguel Angel Moreno, Silvia Catot, Christian Rolfo, Noemi Reguart, Ramon Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Angel Molina, Jose Javier Sanchez, Miquel Taron, None, Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer The New England Journal of Medicine. ,vol. 361, pp. 958- 967 ,(2009) , 10.1056/NEJMOA0904554
Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Aleksandra Szczésna, Erzsébet Juhász, Emilio Esteban, Olivier Molinier, Wolfram Brugger, Ivan Melezínek, Gaëlle Klingelschmitt, Barbara Klughammer, Giuseppe Giaccone, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncology. ,vol. 11, pp. 521- 529 ,(2010) , 10.1016/S1470-2045(10)70112-1
Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai-Hong I. Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, WeiWei Tan, Leena Gandhi, Mari Mino-Kenudson, Greg C. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 363, pp. 1693- 1703 ,(2010) , 10.1056/NEJMOA1006448
David M. Jackman, Beow Y. Yeap, Neal I. Lindeman, Panos Fidias, Michael S. Rabin, Jennifer Temel, Arthur T. Skarin, Matthew Meyerson, Alison J. Holmes, Ana M. Borras, Boris Freidlin, Patricia A. Ostler, Joan Lucca, Thomas J. Lynch, Bruce E. Johnson, Pasi A. Jänne, Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 760- 766 ,(2007) , 10.1200/JCO.2006.07.5754
Ahmedin Jemal, Freddie Bray, Melissa M. Center, Jacques Ferlay, Elizabeth Ward, David Forman, Global cancer statistics CA: A Cancer Journal for Clinicians. ,vol. 61, pp. 69- 90 ,(1999) , 10.3322/CAAC.20107
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X
Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts, Vittorio Gebbia, Paolo Maione, Floriana Morgillo, Giovenzio Genestreti, Adolfo Favaretto, Natasha Leighl, Rafal Wierzbicki, Saverio Cinieri, Yasmin Alam, Salvatore Siena, Giampaolo Tortora, Raffaella Felletti, Ferdinando Riccardi, Gianfranco Mancuso, Antonio Rossi, Flavia Cantile, Ming-Sound Tsao, Mauro Saieg, Gilda da Cunha Santos, Maria Carmela Piccirillo, Massimo Di Maio, Alessandro Morabito, Francesco Perrone, First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial Journal of Clinical Oncology. ,vol. 30, pp. 3002- 3011 ,(2012) , 10.1200/JCO.2011.41.2056